InvestorsHub Logo
Followers 129
Posts 23648
Boards Moderated 1
Alias Born 09/14/2016

Re: None

Friday, 04/05/2019 9:44:17 AM

Friday, April 05, 2019 9:44:17 AM

Post# of 1306
BOSTON, MASSACHUSETTS, April 04, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims announced today that the Company has entered into a definitive exclusive licensing agreement with MDX Lifesciences, Inc. (MDX). The licensing agreement will allow Bioxytran to continue commercial development of MDX technology and develop new protocols that measure the tissue metabolic state of the brain.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BIXT News